Skip to main content
Clinical Trials/IRCT20221119056535N1
IRCT20221119056535N1
Recruiting
Phase 3

Investigating the effect of Remifentanil and Labtalol, in combination with Propofol, on hemodynamic changes in nasal endoscopy

Qazvin University of Medical Sciences0 sites50 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Qazvin University of Medical Sciences
Enrollment
50
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Willingness to participate in research with informed consent after giving necessary and sufficient explanations about the study
  • The age of the person should be between 15 and 60 years
  • There is no history of surgery and it is the patient's first surgery
  • Not having a chronic mental or physical illness (schizophrenia, diabetes, etc.)
  • Not having vision and hearing problems and other disabilities
  • No allergy to Remifentanil, Profol and Labtalol
  • Absence of pregnancy, breastfeeding and abortion less than 3 months

Exclusion Criteria

  • Heart diseases and HTN
  • Liver diseases (cirrhosis, hepatitis, etc.)

Outcomes

Primary Outcomes

Not specified

Similar Trials